Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Similar articles for PubMed (Select 23406733)

1.

Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.

Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y.

Ann Oncol. 2013 Jun;24(6):1498-505. doi: 10.1093/annonc/mdt011. Epub 2013 Feb 13.

2.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EG, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC.

Ann Oncol. 2011 Jul;22(7):1561-70. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6.

3.

BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.

Chen Y, Zhou J, Xu Y, Li Z, Wen X, Yao L, Xie Y, Deng D.

Cancer Sci. 2009 Sep;100(9):1663-7. doi: 10.1111/j.1349-7006.2009.01225.x. Epub 2009 May 18.

PMID:
19522853
4.

Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.

Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF.

PLoS One. 2013;8(2):e56256. doi: 10.1371/journal.pone.0056256. Epub 2013 Feb 6. Erratum in: PLoS One. 2014;9(3):e93778.

5.

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.

Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J.

Breast Cancer Res Treat. 2013 Sep;141(2):205-12. doi: 10.1007/s10549-013-2693-9. Epub 2013 Sep 13.

PMID:
24026861
6.

MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.

Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.

Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.

PMID:
23860775
7.

Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.

Harada H, Miyamoto K, Yamashita Y, Nakano K, Taniyama K, Miyata Y, Ohdan H, Okada M.

Cancer. 2013 Feb 15;119(4):792-8. doi: 10.1002/cncr.27754. Epub 2013 Jan 18.

8.

BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation.

Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2011 Aug;129(1):69-77. doi: 10.1007/s10549-010-1188-1. Epub 2010 Sep 30.

PMID:
20882403
9.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.

Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

10.

Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.

Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.

Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.

PMID:
22228432
11.

Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.

Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P.

Epigenetics. 2013 Jan;8(1):105-12. doi: 10.4161/epi.23319. Epub 2012 Dec 18.

12.

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.

Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R.

Cancer Chemother Pharmacol. 2014 Apr;73(4):771-8. doi: 10.1007/s00280-014-2404-1. Epub 2014 Feb 14.

PMID:
24526178
13.

[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].

Yuan P, Xu Y, Ouyang T, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT, Li JF.

Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):282-6. Chinese.

PMID:
19615284
14.

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.

15.

Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer.

Hasan TN, Leena Grace B, Shafi G, Syed R.

Clin Transl Oncol. 2013 Jul;15(7):555-62. doi: 10.1007/s12094-012-0968-y. Epub 2012 Dec 21.

PMID:
23263908
16.

BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.

Bosviel R, Garcia S, Lavediaux G, Michard E, Dravers M, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.

Cancer Epidemiol. 2012 Jun;36(3):e177-82. doi: 10.1016/j.canep.2012.02.001. Epub 2012 Mar 7.

PMID:
22402307
17.

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.

Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ.

BMC Cancer. 2013 Nov 5;13:523. doi: 10.1186/1471-2407-13-523.

18.

Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.

Al-Moghrabi N, Al-Qasem AJ, Aboussekhra A.

Int J Oncol. 2011 Jul;39(1):129-35. doi: 10.3892/ijo.2011.1021. Epub 2011 Apr 29.

PMID:
21537840
19.

Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.

Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2009 Jul 1;9:217. doi: 10.1186/1471-2407-9-217.

20.

BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.

Otani Y, Miyake T, Kagara N, Shimoda M, Naoi Y, Maruyama N, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Cancer Sci. 2014 Oct;105(10):1369-76. doi: 10.1111/cas.12506. Epub 2014 Oct 1.

PMID:
25155055
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk